Related Experiment Video
Updated: Apr 26, 2026

08:20
Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice
Published on: July 12, 2018
12.8K
Banana resistant starch and its effects on constipation model mice
Juan Wang1, Ji Hong Huang, Yan Feng Cheng
11 College of Light Industry and Food Sciences, South China University of Technology , Guangzhou, China .
Journal of Medicinal Food
|July 22, 2014
Summary
Banana resistant starch (BRS) effectively accelerates gastrointestinal transit and reduces constipation onset in mice. This study highlights BRS
Area of Science:
- Food Science and Technology
- Gastroenterology
- Biochemistry
Background:
- Constipation is a prevalent gastrointestinal disorder.
- Resistant starch, a type of dietary fiber, has shown potential in modulating gut function.
- Banana resistant starch (BRS) has unique structural properties that warrant investigation for its physiological effects.
Purpose of the Study:
- To characterize the structural properties of banana resistant starch (BRS).
- To evaluate the effects of BRS on gastrointestinal transit and dejecta in a mouse model of constipation.
- To determine the optimal dosage of BRS for improving intestinal motility.
Main Methods:
- Banana resistant starch (BRS) was extracted and its physicochemical properties (crystallinity, molecular weight, particle morphology) were analyzed.
- A mouse constipation model was induced using diphenoxylate.
- Mice were gavaged with varying doses of BRS (1.0, 2.0, 4.0 g/kg body weight), and gastrointestinal transit, dejecta characteristics, body weight, and food intake were monitored.
Main Results:
- BRS particles were oval and spindly with surface cracks and pits, exhibiting a crystallinity of 23.13%.
- BRS administration at 4.0 g/kg increased gastrointestinal propulsive rate.
- BRS at 2.0 and 4.0 g/kg shortened the time to the first defecation without affecting dejecta quality, body weight, or food intake.
Conclusions:
- Banana resistant starch (BRS) effectively accelerates small intestinal movement and shortens defecation time in constipated mice.
- BRS demonstrates potential as a functional ingredient for improving intestinal motility.
- Further research is warranted to explore the therapeutic applications of BRS in managing constipation.
Related Concept Videos
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
899
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
899
Drugs for Treatment of Constipation-Predominant IBS
1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K

